Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, Suite 1350, Cambridge, MA
Fiscal year end
December 31
Former names
Cullinan Oncology, Inc. (to 4/2/2024), Cullinan Management, Inc. (to 2/22/2021), Cullinan Oncology, LLC (to 1/6/2021)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.12K % +11.7%
Debt-to-equity 4.59 % -18.7%
Return On Equity -29.1 % +9.34%
Return On Assets -27.8 % +8.42%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58.5M shares +35.9%
Common Stock, Shares, Outstanding 58.5M shares +36.4%
Entity Public Float 1B USD +167%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 58.3M shares +36.5%
Weighted Average Number of Shares Outstanding, Diluted 58.3M shares +36.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 143M USD -3.55%
General and Administrative Expense 54M USD +27.1%
Operating Income (Loss) -197M USD -3.05%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -169M USD -212%
Income Tax Expense (Benefit) -14.1M USD -134%
Net Income (Loss) Attributable to Parent -167M USD -9.29%
Earnings Per Share, Basic -2.84 USD/shares +24.9%
Earnings Per Share, Diluted -2.84 USD/shares +23.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 83M USD -15.7%
Cash, Cash Equivalents, and Short-term Investments 399M USD
Other Assets, Current 3.9M USD
Assets, Current 415M USD -13.6%
Other Long-term Investments 15.5M USD -49.5%
Property, Plant and Equipment, Net 683K USD -30.9%
Operating Lease, Right-of-Use Asset 1.67M USD -34.4%
Other Assets, Noncurrent 366K USD -20.3%
Assets 622M USD +28.4%
Accounts Payable, Current 1.68M USD -32.5%
Accrued Liabilities, Current 27.7M USD +14.3%
Liabilities, Current 30.6M USD +8.92%
Operating Lease, Liability, Noncurrent 849K USD -60.5%
Liabilities 31.5M USD +3.99%
Accumulated Other Comprehensive Income (Loss), Net of Tax -133K USD -3.1%
Retained Earnings (Accumulated Deficit) -368M USD -83.3%
Stockholders' Equity Attributable to Parent 590M USD +30.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 590M USD +30.1%
Liabilities and Equity 622M USD +28.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD +25%
Net Cash Provided by (Used in) Financing Activities 1.09M USD -39.4%
Net Cash Provided by (Used in) Investing Activities 13M USD -14.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 58.5M shares +36.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 131M USD +49.9%
Deferred Tax Assets, Gross 132M USD +49%
Operating Lease, Liability 2.15M USD -40.1%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -167M USD -11.1%
Lessee, Operating Lease, Liability, to be Paid 2.33M USD -42.7%
Property, Plant and Equipment, Gross 1.34M USD 0%
Operating Lease, Liability, Current 1.3M USD -9.58%
Lessee, Operating Lease, Liability, to be Paid, Year Two 872K USD -40.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.46M USD -15.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 182K USD -62.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 872K USD -40.3%
Deferred Tax Assets, Operating Loss Carryforwards 32.1M USD +123%
Preferred Stock, Shares Issued 648K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 648K shares 0%
Depreciation, Depletion and Amortization 76K USD +5.56%
Deferred Tax Assets, Net of Valuation Allowance 604K USD -33.9%
Share-based Payment Arrangement, Expense 37.8M USD +24.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%